HNSPF (Hansoh Pharmaceutical Group Co) Other Current Assets: $43 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HNSPF Hansoh Pharmaceutical Group Co Ltd HNSPF
91 GF Score
Price $3.83
GF Value $3.65
Valuation Fairly Valued
View Full Analysis

What is Hansoh Pharmaceutical Group Co Other Current Assets?

Hansoh Pharmaceutical Group Co HNSPF 91 Other Current Assets is $43 Mil as of Dec. 2025. GuruFocus rates HNSPF with a GF Score™ of 91/100 and a GF Value™ of $3.65 (Fairly Valued).

Hansoh Pharmaceutical Group Co's other current assets for the quarter that ended in Dec. 2025 was $43 Mil.

Hansoh Pharmaceutical Group Co's quarterly other current assets declined from Dec. 2024 ($29 Mil) to Jun. 2025 ($0 Mil) but then increased from Jun. 2025 ($0 Mil) to Dec. 2025 ($43Mil).

Hansoh Pharmaceutical Group Co's annual other current assets declined from Dec. 2023 ($31 Mil) to Dec. 2024 ($29 Mil) increased from Dec. 2024 ($29 Mil) to Dec. 2025 ($43 Mil).


Hansoh Pharmaceutical Group Co Other Current Assets Related Terms


Hansoh Pharmaceutical Group Co Other Current Assets Historical Data

* Premium members only.

The historical data trend for Hansoh Pharmaceutical Group Co's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansoh Pharmaceutical Group Co Other Current Assets Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.15 21.15 31.17 29.06 42.96

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.17 0.00 29.06 0.00 42.96
HNSPF
91GF Score
Hansoh Pharmaceutical Group Co Ltd HNSPF
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansoh Pharmaceutical Group Co Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $43 Mil mean?
Hansoh Pharmaceutical Group Co (HNSPF) has a Other Current Assets of $43 Mil as of Dec. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Hansoh Pharmaceutical Group Co.
Is Hansoh Pharmaceutical Group Co's Other Current Assets too high?
Hansoh Pharmaceutical Group Co's current Other Current Assets is $43 Mil. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's Other Current Assets compare to ZTS and UTHR?
Hansoh Pharmaceutical Group Co's Other Current Assets of $43 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Drug Manufacturers company?
A good Other Current Assets depends on the Drug Manufacturers industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Hansoh Pharmaceutical Group Co. Hansoh Pharmaceutical Group Co's current Other Current Assets is $43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Fairly Valued. The stock's GF Value™ is $3.65, compared to a current price of $3.83 — trading 4.8% above its estimated fair value. The current Other Current Assets is $43 Mil. Hansoh Pharmaceutical Group Co's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current Other Current Assets is $43 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?

Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued. The current stock price of $3.83 is trading 4.8% above its estimated GF Value™ of $3.65. GuruFocus considers Hansoh Pharmaceutical Group Co to be Fairly Valued.

Key valuation signals for HNSPF:

  • Other Current Assets: $43 Mil
  • GF Value™: $3.65 vs. price of $3.83 (4.8% above fair value)
  • GF Score™: 91/100

No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hansoh Pharmaceutical Group Co Business Description

Address No. 287 Xiangke Road, Pudong New Area, Shanghai, CHN
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
91GF Score

Get the complete analysis for HNSPF

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.83
Price
$3.65
GF Value